CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 16 enrolled
Drug / intervention
CT1812 +1 moredrug
Likely dose
CT1812 300mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04735536
NCT04735536Phase 2Completed
CompareCT.gov

A Pilot Electroencephalography (EEG) Study to Evaluate the Effect of CT1812 Treatment on Synaptic Activity in Subjects With Mild to Moderate Alzheimer's Disease

Cognition Therapeutics·interventional·Posted Feb 3, 2021·Updated Nov 29, 2024

In Brief

A Phase 2 clinical trial evaluating CT1812 and Placebo for Alzheimer Disease. Completed, enrolled 16 participants across 1 site.

Detailed Summary

This is a single-site, randomized, double-blind, placebo-controlled, 29-day, 2-period crossover Phase 2 study of 1 dose level of CT1812 (active) or placebo in adults with mild to moderate AD.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer Disease
CountriesNetherlands
CollaboratorsNational Institute on Aging (NIA)

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedFeb 3, 2021
Enrollment StartJul 9, 2020
Primary CompletionApr 26, 2023
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 5.4 years ago

Interventions

CT1812drug

Active Treatment- CT1812 at a dose of 300mg

Placeboother

Placebo Comparator